Key statistics dashboard for Septerna Inc (SEPN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Stock Data
| Price | $38.44 |
| Market Cap | $1.7B |
| Enterprise Value | $1.67B |
| Beta | 3.50 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -70.44 |
| Price / Book | 4.43 |
| P/S | 17.34 |
| EV/EBITDA | -42.03 |
| EV/Sales | 16.89 |
| EV/FCF | 15.90 |
| P/FCF | 16.32 |
| Earnings Yield | -1.40% |
| FCF Yield | 6.07% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 99.57% |
| EBIT Margin | -41.44% |
| EBITDA Margin | -40.20% |
| Operating Margin | -44.04% |
| Net Margin | -24.51% |
| Return on Equity | -6.31% |
| Return on Assets | -4.28% |
| Return on Invested Capital | -8.89% |
| Return on Capital Employed | -8.93% |
Financial Health
| Current Ratio | 4.99 |
| Quick Ratio | 4.99 |
| Cash Ratio | 1.07 |
| Debt / Equity | 0.06 |
| Debt / Assets | 3.98% |
| Net Debt / EBITDA | 1.56 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 2.20 |
| Book Value per share | 8.59 |
| Cash per share | 8.27 |
| FCF per share | 2.33 |
| Tangible Book Value per share | 8.59 |
| Dividend per share | 0.00 |
Related companies: ABUS · BCAX · EYPT · FTRE · KURA · MRVI · NRIX
Explore sector: Healthcare · Biotechnology
More sections of SEPN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks